Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Earnings
Pharma
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis' CEO remains unfazed by the threat of Merck's newly approved oral PCSK9 inhibitor, Lipfendra, to his company's injectable Leqvio.
Angus Liu
Jul 21, 2026 10:36am
Why Legend Biotech stock fell 10% despite record Carvykti sales
Jul 20, 2026 11:11am
Takeda swings to loss for '25 with hefty jury verdict
Jun 5, 2026 11:30am
Takeda's $1.3B savings drive to impact 4,500 roles in '26
May 13, 2026 11:41am
Daiichi Sankyo targets global top 5 oncology rank by 2035
May 11, 2026 10:22am
Gilead says long-acting PrEP Yeztugo in line for $1B in '26 sales
May 8, 2026 11:30am
